Heart failure & cardiomyopathiesSecondary analysis
Impact of Aficamten on Disease and Symptom Burden in Obstructive Hypertrophic Cardiomyopathy
- Secondary analysis of the SEQUOIA-HCM randomised trial
- responder analysis
Authors' conclusion
Treatment with aficamten was associated with substantial improvements across a broad range of clinically relevant efficacy measures.
Study context
- Population
- Symptomatic patients with obstructive hypertrophic cardiomyopathy (oHCM)
- Participants
- 142 vs 140
- Comparison
- Aficamten vs placebo
- Aficamtenn = 142
- Placebon = 140reference
Primary result
As reported in the abstract
Responder outcomes · 24 weeks
Relief in limiting symptoms
Complete hemodynamic response
Enhanced exercise capacity
≥50% decrease in NT-proBNP
Improvement in ≥1 outcome
| Outcome | Aficamten | Placebo |
|---|---|---|
| All 4 outcomes | 23% | 0 |
Further findings
No longer eligible for septal reduction therapy (among those eligible at baseline) · 24 weeks
P = 0.002
eligible at baseline Aficamten 32 · Placebo 29
Original publication
Impact of Aficamten on Disease and Symptom Burden in Obstructive Hypertrophic Cardiomyopathy. J Am Coll Cardiol. Published 30 September 2024. doi:10.1016/j.jacc.2024.09.003
Summarised from the published abstract; every number is checked against it